Titre : Myopathie à axe central

Myopathie à axe central : Questions médicales fréquentes

Termes MeSH sélectionnés :

Lymphatic Metastasis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Myopathie à axe central : Questions médicales les plus fréquentes", "headline": "Myopathie à axe central : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Myopathie à axe central : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-04", "dateModified": "2025-03-01", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Myopathie à axe central" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Myopathies congénitales structurales", "url": "https://questionsmedicales.fr/mesh/D020914", "about": { "@type": "MedicalCondition", "name": "Myopathies congénitales structurales", "code": { "@type": "MedicalCode", "code": "D020914", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.668.491.550" } } }, "about": { "@type": "MedicalCondition", "name": "Myopathie à axe central", "alternateName": "Myopathy, Central Core", "code": { "@type": "MedicalCode", "code": "D020512", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "David Lacomis", "url": "https://questionsmedicales.fr/author/David%20Lacomis", "affiliation": { "@type": "Organization", "name": "Departments of Neurology and Pathology (Neuropathology), University of Pittsburgh School of Medicine, Pittsburgh, PA." } }, { "@type": "Person", "name": "Ichizo Nishino", "url": "https://questionsmedicales.fr/author/Ichizo%20Nishino", "affiliation": { "@type": "Organization", "name": "Department of Neuromuscular Research, National Center of Neurology and Psychiatry (NCNP), National Institute of Neuroscience, 4-1-1 Ogawahigashi, Tokyo 187-8502, Japan; Medical Genome Center, NCNP, Tokyo, Kodaira, Japan. Electronic address: nishino@ncnp.go.jp." } }, { "@type": "Person", "name": "John Rendu", "url": "https://questionsmedicales.fr/author/John%20Rendu", "affiliation": { "@type": "Organization", "name": "INSERM, GIN-U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, University Grenoble Alpes, Bat EJ Safra, Chemin Fortuné Ferrini, La Tronche, Grenoble, France." } }, { "@type": "Person", "name": "Julien Fauré", "url": "https://questionsmedicales.fr/author/Julien%20Faur%C3%A9", "affiliation": { "@type": "Organization", "name": "INSERM, GIN-U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, University Grenoble Alpes, Bat EJ Safra, Chemin Fortuné Ferrini, La Tronche, Grenoble, France." } }, { "@type": "Person", "name": "Satoru Noguchi", "url": "https://questionsmedicales.fr/author/Satoru%20Noguchi", "affiliation": { "@type": "Organization", "name": "Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 187-8502 Tokyo, Japan; Department of Genome Medicine Development, Medical Genome Center, National Center of Neurology and Psychiatry, 187-8551 Tokyo, Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Lymphatic Contrast-enhanced US to Improve the Diagnosis of Cervical Lymph Node Metastasis from Thyroid Cancer.", "datePublished": "2023-04-04", "url": "https://questionsmedicales.fr/article/37014243", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1148/radiol.221265" } }, { "@type": "ScholarlyArticle", "name": "Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer.", "datePublished": "2023-09-08", "url": "https://questionsmedicales.fr/article/37684509", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00432-023-05354-1" } }, { "@type": "ScholarlyArticle", "name": "UBE2S interacting with TRIM21 mediates the K11-linked ubiquitination of LPP to promote the lymphatic metastasis of bladder cancer.", "datePublished": "2023-07-08", "url": "https://questionsmedicales.fr/article/37422473", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41419-023-05938-2" } }, { "@type": "ScholarlyArticle", "name": "IRF2BP2 drives lymphatic metastasis in OSCC cells by elevating mitochondrial fission-dependent fatty acid oxidation.", "datePublished": "2023-09-22", "url": "https://questionsmedicales.fr/article/37737489", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/mc.23635" } }, { "@type": "ScholarlyArticle", "name": "Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer.", "datePublished": "2023-02-08", "url": "https://questionsmedicales.fr/article/36606578", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1530/ERC-22-0221" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système nerveux", "item": "https://questionsmedicales.fr/mesh/D009422" }, { "@type": "ListItem", "position": 3, "name": "Maladies neuromusculaires", "item": "https://questionsmedicales.fr/mesh/D009468" }, { "@type": "ListItem", "position": 4, "name": "Maladies musculaires", "item": "https://questionsmedicales.fr/mesh/D009135" }, { "@type": "ListItem", "position": 5, "name": "Myopathies congénitales structurales", "item": "https://questionsmedicales.fr/mesh/D020914" }, { "@type": "ListItem", "position": 6, "name": "Myopathie à axe central", "item": "https://questionsmedicales.fr/mesh/D020512" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Myopathie à axe central - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Myopathie à axe central", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Myopathie à axe central", "description": "Comment diagnostique-t-on la myopathie à axe central ?\nQuels tests génétiques sont utilisés ?\nQuels signes cliniques sont observés ?\nL'IRM est-elle utile pour le diagnostic ?\nQuel rôle joue l'historique familial ?", "url": "https://questionsmedicales.fr/mesh/D020512?mesh_terms=Lymphatic+Metastasis&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Myopathie à axe central", "description": "Quels sont les principaux symptômes ?\nLa myopathie affecte-t-elle tous les muscles ?\nY a-t-il des symptômes respiratoires ?\nLes symptômes varient-ils selon l'âge ?\nDes troubles de la marche sont-ils fréquents ?", "url": "https://questionsmedicales.fr/mesh/D020512?mesh_terms=Lymphatic+Metastasis&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Myopathie à axe central", "description": "Peut-on prévenir la myopathie à axe central ?\nLe dépistage est-il recommandé ?\nDes conseils de vie peuvent-ils aider ?\nLes activités physiques sont-elles bénéfiques ?\nLes consultations régulières sont-elles nécessaires ?", "url": "https://questionsmedicales.fr/mesh/D020512?mesh_terms=Lymphatic+Metastasis&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Myopathie à axe central", "description": "Quels traitements sont disponibles ?\nLes médicaments sont-ils efficaces ?\nLa chirurgie est-elle une option ?\nComment la rééducation aide-t-elle ?\nY a-t-il des traitements expérimentaux ?", "url": "https://questionsmedicales.fr/mesh/D020512?mesh_terms=Lymphatic+Metastasis&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Myopathie à axe central", "description": "Quelles complications peuvent survenir ?\nLa myopathie peut-elle affecter la vie quotidienne ?\nY a-t-il un risque de cardiomyopathie ?\nLes infections sont-elles plus fréquentes ?\nComment gérer les complications ?", "url": "https://questionsmedicales.fr/mesh/D020512?mesh_terms=Lymphatic+Metastasis&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Myopathie à axe central", "description": "Quels sont les facteurs de risque génétiques ?\nL'âge est-il un facteur de risque ?\nLe sexe influence-t-il le risque ?\nDes facteurs environnementaux jouent-ils un rôle ?\nLes maladies associées augmentent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D020512?mesh_terms=Lymphatic+Metastasis&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on la myopathie à axe central ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique, l'électromyogramme et la biopsie musculaire." } }, { "@type": "Question", "name": "Quels tests génétiques sont utilisés ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques peuvent identifier des mutations dans le gène RYR1, associé à cette myopathie." } }, { "@type": "Question", "name": "Quels signes cliniques sont observés ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "On observe souvent une faiblesse musculaire proximale et des anomalies dans les biopsies musculaires." } }, { "@type": "Question", "name": "L'IRM est-elle utile pour le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IRM peut montrer des anomalies musculaires caractéristiques de la myopathie à axe central." } }, { "@type": "Question", "name": "Quel rôle joue l'historique familial ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Un historique familial de myopathies peut orienter le diagnostic vers une origine génétique." } }, { "@type": "Question", "name": "Quels sont les principaux symptômes ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent faiblesse musculaire, fatigue et parfois des douleurs musculaires." } }, { "@type": "Question", "name": "La myopathie affecte-t-elle tous les muscles ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle touche principalement les muscles proximaux, comme ceux des hanches et des épaules." } }, { "@type": "Question", "name": "Y a-t-il des symptômes respiratoires ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Dans certains cas, la faiblesse musculaire peut affecter les muscles respiratoires." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent apparaître dès l'enfance ou à l'âge adulte, selon les cas." } }, { "@type": "Question", "name": "Des troubles de la marche sont-ils fréquents ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la faiblesse musculaire peut entraîner des difficultés à marcher ou à se lever." } }, { "@type": "Question", "name": "Peut-on prévenir la myopathie à axe central ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Étant génétique, il n'existe pas de prévention, mais un diagnostic précoce aide à la gestion." } }, { "@type": "Question", "name": "Le dépistage est-il recommandé ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Le dépistage génétique peut être conseillé pour les familles à risque de transmission." } }, { "@type": "Question", "name": "Des conseils de vie peuvent-ils aider ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des conseils sur l'exercice et la nutrition peuvent améliorer la qualité de vie des patients." } }, { "@type": "Question", "name": "Les activités physiques sont-elles bénéfiques ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des activités adaptées peuvent aider à maintenir la force musculaire et la mobilité." } }, { "@type": "Question", "name": "Les consultations régulières sont-elles nécessaires ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des suivis réguliers permettent d'ajuster les traitements et surveiller l'évolution." } }, { "@type": "Question", "name": "Quels traitements sont disponibles ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de traitement curatif, mais la physiothérapie aide à maintenir la force musculaire." } }, { "@type": "Question", "name": "Les médicaments sont-ils efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments peuvent être prescrits pour gérer les symptômes, mais leur efficacité varie." } }, { "@type": "Question", "name": "La chirurgie est-elle une option ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La chirurgie n'est généralement pas indiquée, sauf pour des complications spécifiques." } }, { "@type": "Question", "name": "Comment la rééducation aide-t-elle ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La rééducation physique aide à améliorer la fonction musculaire et la qualité de vie." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des essais cliniques explorent des thérapies géniques et des traitements ciblés." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des problèmes respiratoires et des déformations musculo-squelettiques." } }, { "@type": "Question", "name": "La myopathie peut-elle affecter la vie quotidienne ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la faiblesse musculaire peut limiter les activités quotidiennes et l'autonomie." } }, { "@type": "Question", "name": "Y a-t-il un risque de cardiomyopathie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines formes de myopathie peuvent être associées à des problèmes cardiaques." } }, { "@type": "Question", "name": "Les infections sont-elles plus fréquentes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les infections peuvent survenir en raison de la faiblesse musculaire et de l'immobilité." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Une prise en charge multidisciplinaire est essentielle pour gérer les complications." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque génétiques ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux de myopathies augmentent le risque de développer cette maladie." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "L'âge d'apparition peut varier, mais les symptômes se manifestent souvent dans l'enfance." } }, { "@type": "Question", "name": "Le sexe influence-t-il le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Les myopathies peuvent affecter les deux sexes, mais certaines formes sont plus fréquentes chez les hommes." } }, { "@type": "Question", "name": "Des facteurs environnementaux jouent-ils un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, les facteurs environnementaux ne sont pas clairement établis comme des risques." } }, { "@type": "Question", "name": "Les maladies associées augmentent-elles le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines maladies auto-immunes peuvent coexister avec la myopathie, mais leur lien n'est pas direct." } } ] } ] }

Sources (10000 au total)

Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer.

In ovarian cancer, there are two main routes of metastasis, namely intraperitoneal and retroperitoneal. Their biologic background is poorly understood. Identifying molecular markers involved might ena... In our study, quantitative and qualitative protein Ang-2 expression in tumor tissue of ovarian cancer patients was analyzed by Western blot (n = 138) and immunohistochemistry (n = 58). Further, Ang-2 ... We observed that Ang-2 expression is significantly higher in tumors with retroperitoneal dissemination (pT1a-pT3b, pN1) compared to those showing intraperitoneal tumor growth (pT3c, pN0). In addition,... All in all, Ang-2 may serve as a molecular marker for patients with tumors prone to spread to lymph nodes and for patients who might benefit from bevacizumab therapy....

Potential functions and mechanisms of lysine crotonylation modification (Kcr) in tumorigenesis and lymphatic metastasis of papillary thyroid cancer (PTC).

To examine the putative functions and mechanisms of lysine crotonylation (Kcr) during the development and progression of papillary thyroid cancer (PTC).... Samples of thyroid cancer tissues were collected and subjected to liquid chromatography-tandem mass spectrometry. Crotonylated differentially expressed proteins (DEPs) and differentially expressed Kcr... A total of 262 crotonylated DEPs and 702 DEKSs were quantitated. First, for the tumor/normal comparison, a dynamic expression model analysis (Mfuzz) of the DEKSs revealed that clusters 1, 3, and 4 inc... Higher Kcr expression was correlated with thyroid tumorigenesis and lymphatic metastasis, which may regulate thyroid cancer progression by Pyruvate metabolism, TCA cycle, Cell cycle, and other pathway...

Can quantitative parameters of spectral computed tomography predict lymphatic metastasis in lung cancer? a systematic review and meta-analysis.

This study evaluated the use of quantitative spectral computed tomography (CT) parameters to identify lymph node metastasis (LM) in lung cancer.... Literature about LM in lung cancer diagnosed using spectral CT up to September 2022 was retrieved from the PubMed, EMBASE, Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure, ... Eleven studies, including 1,290 cases, without obvious publication bias were enrolled. In eight articles, the pooled AUC of NIC in the arterial phase (AP) was 0.84 (SEN = 0.85, SPE = 0.74, +LR = 3.3, ... Spectral CT is a suitable noninvasive and cost-effective method for determining LM in lung cancer. Additionally, NIC and λHU in the AP have good discrimination ability than short-axis diameter, provid...

Single-cell RNA sequencing reveals tumor immune microenvironment in human hypopharygeal squamous cell carcinoma and lymphatic metastasis.

Human hypopharygeal squamous cell carcinoma (HSCC) is a common head and neck cancer with a poor prognosis in advanced stages. The occurrence and development of tumor is the result of mutual influence ... We performed single-cell RNA sequencing (scRNA-seq) and analysis of hypopharyngeal carcinoma, paracancerous, and lymphoid tissues from five HSCC patients. Subdivide of B cells, T cells, macrophages ce... Transcriptome profiles of 132,869 single cells were obtained and grouped into seven cell clusters, including epithelial cells, lymphocytes, mononuclear phagocytics system (MPs), fibroblasts, endotheli... Overall, this study revealed TIME in HSCC and lymphatic metastasis, and provided potential therapeutic targets for HSCC....